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Alzheimer’s disease (AD) is conceptualized as a progressive consequence of two hallmark pathological changes in
grey matter: extracellular amyloid plaques and neurofibrillary tangles. However, over the past several years,
neuroimaging studies have implicated micro- and macrostructural abnormalities in white matter in the risk and
progression of AD, suggesting that in addition to the neuronal pathology characteristic of the disease, white matter
degeneration and demyelination may be also important pathophysiological features. Here we review the evidence
for white matter abnormalities in AD with a focus on myelin and oligodendrocytes, the only source of myelination
in the central nervous system, and discuss the relationship between white matter changes and the hallmarks of
Alzheimer’s disease. We review several mechanisms such as ischemia, oxidative stress, excitotoxicity, iron overload,
Aβ toxicity and tauopathy, which could affect oligodendrocytes. We conclude that white matter abnormalities, and
in particular myelin and oligodendrocytes, could be mechanistically important in AD pathology and could be
potential treatment targets.
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Alzheimer’s disease (AD) is conceptualized as a pro-
gressive consequence of two hallmark pathological
changes: extracellular neuritic plaques, which are
composed of amyloid-beta (Aβ) surrounded by dys-
trophic neuritic processes, and neurofibrillary tangles,
which are intraneuronal aggregates of insoluble
cytoskeletal elements, composed mainly of phosphory-
lated tau protein. These pathological changes are
believed to result in neurodegeneration, which can be
appreciated with structural neuroimaging as regional
and global atrophy [73]. Because of the distribution of
this pathology and its associated neurodegeneration,
AD is typically considered a disease of the brain’s
grey matter. However, over the past several years,
neuroimaging studies have implicated micro- and
macrostructural abnormalities in white matter in the
risk and progression of AD, suggesting that in
addition to the neuronal loss characteristic of the* Correspondence: se2351@columbia.edu
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may be important pathophysiological features. Myelin
loss and the inability of the oligodendrocytes, the
cells responsible for the production and maintenance
of myelin, to repair myelin damage may be additional
central features of AD [5, 53, 55, 60]. Because of the
essential role of oligodendrocyte cell lineage in myelin
production and remyelination processes, changes in
the number of oligodendrocytes or their precursor
cells and/or their dysfunction can affect myelin inte-
grity and therefore be potentially implicated in AD
pathogenesis.
The purpose of this review is to discuss the evi-
dence for white matter abnormalities in AD with a
focus on myelin damage and oligodendrocyte lineage
cells and to review the relationship between white
matter changes and the pathological hallmarks of
AD. In addition, we discuss whether white matter
changes are a secondary result of cortical AD path-
ology or whether they contribute directly or indir-
ectly to the pathogenesis and clinical manifestation
of AD.le is distributed under the terms of the Creative Commons Attribution 4.0
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studies
The observation that neuroimaging-defined white matter
abnormalities are characteristic of AD is relatively new.
Work from our laboratory, for example, demonstrated that
the burden of white matter hyperintensities (WMH), dis-
tributed signal abnormalities visualized on T2-weighted
magnetic resonance imaging (MRI), predicts incident AD
[18, 19, 21], the rate of cognitive decline among individuals
with prevalent AD [78], and is associated with genetic risk
factors for late onset AD [20]. We recently showed in the
Dominantly Inherited Alzheimer’s Network that WMH vol-
ume is elevated among individuals with autosomal domin-
ant, fully penetrant mutations for AD up to 20 years before
the expected onset of symptoms, demonstrating that white
matter abnormalities are indeed a core feature of AD. Fur-
thermore, the appearance of WMH in these patients
emerges contemporaneously with AD-related cerebrospinal
fluid (CSF) amyloid and tau abnormalities [49]. WMH se-
verity also correlates with CSF levels of Aβ1–42 in preclin-
ical AD [49] and predicts increasing CSF tau levels in
individuals with mild cognitive impairment [79]. White
matter hyperintensity severity is associated with cerebro-
spinal fluid (CSF) amyloid levels independent of vascular
risk factors [71].
The important role of vascular disease in the deve-
lopment of white matter damage should be emphasized.
White matter hyperintensities tend to be distributed in
brain areas with relatively low perfusion levels, particularly
in the deep, periventricular white matter. The density of
vessels in these areas decreases both with normal aging
and in AD [23], consistent with reports of decreased blood
flow to white matter [69], which could cause hypoxic/is-
chemic damage in these areas. White matter hyperintensi-
ties are related to small vessel disease, and inflammation
[26, 61, 64], but comprehensive analysis of postmortem
tissue in areas known to be affected by WMH, including
evaluation of possible hypoxic damage to oligodendrocyte
lineage cells, has not been completed. A recent study re-
ported that parietal WMH pathogenesis in AD is related
to axonal loss, through Wallerian-like degeneration, which
corresponds to cortical phosphorylated tau burden, and
demyelination in patients with AD but to vasculopathy
and ischemia (by sclerotic index as a marker of small ves-
sel disease and myelin associated glycoprotein to proteoli-
pid protein ratio as a measure of hypoperfusion) in
individuals without AD, suggesting that some degree of
WMH is secondary to neurodegeneration in the context
of AD [57]. However, neuroimaging studies showed that
white matter networks are defective in preclinical AD, at a
time when neurodegenerative changes, cortical atrophy, or
cortical glucose reduction were not apparent [33]. Vascu-
lar and blood brain barrier (BBB) impairments, small
hemorrhagic lesions and buildup of iron have beenreported in the brains of AD patients even in the preclin-
ical stages of the disease [86].
Histopathological evidence of white matter abnormalities
The neuroimaging studies establish that there is some de-
gree of white matter abnormality in the context of AD,
which may be radiological manifestations of more wide-
spread white matter pathological abnormalities. White mat-
ter hyperintensities have been associated histopathologically
with myelin pallor, myelin loss [31, 38] (as shown in Fig. 1)
and the loss of myelinated axons, as well as changes in ar-
terial adventitia in deep white matter [68]. In our aim to re-
view the widespread white matter abnormalities, we focus
on the changes in the myelin sheath and oligodendrocyte
lineage cells.
Myelin damage
In the normal development of the central nervous system
(CNS), different brain regions are myelinated at different
times. Myelination begins in the fourth month of human
embryonic development and continues until the third or
fourth decade of life [22, 47] . In general, the spinal cord
and brain stem myelinate earlier, while other areas, such as
the telencephalon, the entorhinal cortex, hippocampus and
the amygdala myelinate later [17, 30]. Diffusion tensor im-
aging studies show the development of association tracts in
post-adolescent subjects [47]. In addition, there is a particu-
lar susceptibility for demyelination in areas that are
myelinated at older ages, a phenomenon referred to as
“neuropathologic retrogenesis” [8, 12, 17, 66, 76]. Myelin
loss has been observed consistently in AD and the later-
myelinated areas are also most vulnerable [13, 36, 65]. They
demonstrate significantly greater myelin loss compared with
areas that myelinate earlier [6]. Analysis of postmortem
brain tissue of AD patients has revealed that the white mat-
ter is altered chemically, compared with that of patients
without dementia: the amounts of total protein, myelin
basic protein (MBP), myelin proteolipid protein (PLP), Cyc-
lic nucleotide phosphohydrolase (CNPase), and cholesterol
is significantly decreased, indicating a loss of myelin. White
matter fatty acid ratios are also altered in AD [67].
White matter and myelin changes in AD need to be
taken with respect to changes during aging. For example,
the overall hemispheric white matter volume decreases
with age [50]. How much of this is due to changes in water
content or water infusibility is not completely clear [42].
However, a decrease in the total length of myelinated fi-
bers, reaching a 45% decrease from 20 to 80 year-old indi-
viduals and the appearance of thinner axons has been
reported [50]. Thus, a number of investigations conclude
that with age, myelin production by oligodendrocytes con-
tinues but leads to thinner myelin sheaths and shorter in-
ternodes [50]. Axon caliber decreases in experimental





Fig. 1 This figure demonstrates examples of white matter myelin loss in brain sections from a patient with Alzheimer’s disease. Tissues from
frontal and occipital areas are stained with Luxol fast blue-hematoxylin and eosin (LHE). b2 and b1 represent the regions with and without myelin
pallor in the frontal area, respectively. d2 and d1 represent the regions with and without myelin pallor in the occipital area, respectively. The scale
bars in images a, b, c and d are 1000 μm. The scale bars in images b1, b2, d1 and d2 are 100 μm
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white matter deficits due to conduction failure and by a
greater vulnerability to trauma, oxidative stress, or Aβ tox-
icity [5]. Axonal loss and demyelination are both associated
with white matter abnormalities in AD and are predictors
of severity of white matter abnormalities [57]. Future stud-
ies with the aim of preventing or repairing myelin damage
could elucidate the impact of white matter changes as one
of the core pathologies of AD.Abnormalities of oligodendrocyte lineage cells in AD
The primary role of oligodendrocytes is to produce
myelin, but they also play a supportive, modulatory
and regulatory role for neurons, including the pro-
duction of neurotrophic factors, inhibition of neurite
growth, and stabilization of neuronal connectivity
[44, 70]. The adult central nervous system contains
both precursor cells for oligodendrocytes in addition
to mature, myelinating cells [10]. Oligodendrocyte
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system are capable of proliferating and migrating and
effecting new myelination after demyelinating insults.
Animal studies have shown that during adulthood,
oligodendrocytes are generated from ventricular-
subventricular zone and the new oligodendrocytes
progenitors migrate to white matter tracks from
there [59]. Mature human oligodendrocytes in the
condition of being deprived from their myelin sheath
may return into their previous subtype capacity and
change their phenotype and their myelination pro-
gram [37]. The different oligodendrocyte lineage cells
express changes in morphology during their develop-
ment and maturation [10]. Figure 2 shows an example













Fig. 2 An example of Olig2+ oligodendrocyte distribution throughout the
The insets show Olig2+ nuclei at higher magnification. H&E counterstaining
and grey matter. LV: lateral ventricle; SVWM: subventricular white matter; D
matter. The scale bars in a, b and c are 100 μm and the scale bars in the inareas in an adult postmortem human brain. In mammals,
OPCs, by presence of intrinsic hypoxia-inducible factor
(HIF) signaling, control white matter angiogenesis, axonal
integrity, and the onset of myelination at postnatal stages
[85]. Oligodendrocytes are able to modulate ion homeo-
stasis in the axon environment [60]. OPCs are the specific
glial cells that directly make synapses with neurons; they
build synapses with glutamatergic neurons in the hippo-
campus (rat) [15], cortex (mouse) [24], white matter
tracks (rat) [46] and other areas. However, they only make
postsynaptic connection with neurons. The behavior of
OPCs can be controlled by neurotransmitters and by sur-
rounding neuronal demands. For example, in the pres-
ence of higher neural activity, oligodendrocytes change
the amounts of myelin sheaths, which affects theLV
white matter from a neurologically-healthy adult, postmortem brain.
. Arrowheads: Olig2+ nuclei (brown). Dashed line: the border of white
WM: deep white matter; SCWM: subcortical white matter; GM: grey
sets are 10 μm
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could speculate that neuronal AD pathology, which is
characterized by neuronal and axonal dysfunction, could
alter the amounts of myelin produced by oligodendro-
cytes. This dynamicity of myelin and oligodendrocytes
thus could ultimately affect behavior [58].
A number of human and animal studies investigated
oligodendrocyte changes in AD. In one study, 6–8-
month-old APPPS1 mice showed an increase in the num-
bers of OPCs, while the number of Olig2+ cells in post-
mortem tissues of AD patients was decreased [11].
Another study reported a higher number of MAP-2 posi-
tive remyelinating oligodendrocytes in the areas adjacent
to periventricular white matter lesions and a higher num-
ber of PDGFR-α positive OPCs in white matter lesions
[74]. In a PS1 knock-in mouse model, increased vulner-
ability and death of oligodendrocytes due to glutamate
and Aβ were demonstrated and these cells showed a def-
icit in calcium regulation [60]. This study suggests that
the abnormalities of oligodendrocytes in the presence of a
PS1 mutation could be an early event in the disease
course. Another study demonstrated that MBP and the
number of myelinating oligodendrocytes were decreased
in 6-month old triple transgenic mice (3xTg-AD), the
number of immature oligodendrocytes remained un-
changed and mature non-myelinating cells were increased
[29]. The authors reported that myelinating oligodendro-
cytes are highly sensitive to oxidative stress due to their
higher metabolic demand, higher iron, and lipid content.
Reduction of the diameter of oligodendrocyte nuclei in
AD patients in parahippocampal white matter was also re-
ported [35] while the mean nuclear diameter of neurons
remained unchanged. Alzheimer’s-related changes in oli-
godendrocytes for human studies and animal models are
summarized in Table 1.
One of the frequently accepted themes related to oligo-
dendrocyte damage in AD is that these cells suffer from
oxidative stress, which can be produced by a wide range of
factors. The adult CNS contains oligodendrocyte precursorTable 1 This table summarizes the studies, the specimen that was used
The model and specimen Oligodendrocyte changes
PS1 knock-in mouse Vulnerability and death of OLs
Postmortem AD Increased MAP-2 positive remyelinating
OLs adjacent to WM lesions
Increas
OPCs i
3xTg-AD mouse Decreased myelinating OLs No ch
Postmortem AD Reduced OLs nuclear diameter
in parahippocampal white matter
APPPS1 mouse Increased OPCs number
Postmortem AD Decreased Olig2+
It depicts the verity of the results in different animal models and human studies. PS
platelet-derived growth factor receptor, OPCs oligodendrocyte progenitor cells, WM
mouse with both APP and PS1 transgenescells, which can be mobilized to differentiate into myelinat-
ing oligodendrocytes [10]. Oxidative stress impairs the dif-
ferentiation of OPCs, in part by decreasing the levels of
expression of genes that promote oligodendrocytes differ-
entiation, such as Shh, Sox10 and HDAC3 [34]. In cell cul-
ture, pre-oligodendrocytes show a sensitivity to oxidative
stress and glutathione depletion [2]. In rat cell cultures,
low antioxidant content and high iron capacity, in addition
to excitotoxicity through metabotropic glutamate recep-
tors, makes oligodendrocytes more vulnerable to oxidative
stress [27, 77]. Other factors affecting oligodendrocytes are
listed below.
Aβ and tau: Several studies suggest that Aβ is toxic to
oligodendrocytes [28, 29, 41, 48, 84]. For example, a cell
culture study of rat oligodendrocytes demonstrated that
Aβ-induced oxidative stress can drive oligodendrocyte
death and dysfunction [84]. This study also showed that
mitochondrial DNA damage and the consequent NF-kB
and AP-1 activation are other possible mechanisms of Aβ
toxicity for oligodendrocytes [84]. Note that although
amyloid plaques are exceedingly rare in AD white matter,
the levels of soluble Aβ are elevated in the white matter
[25]. Thus, a direct exposure of white matter oligodendro-
cytes to increased amounts of Aβ is likely. Although there
are toxic effects of Aβ on oligodendrocytes, clinical trials
that have aimed to remove the Aβ plaque in symptomatic
AD patients, did not prevent the progressive neurodegen-
eration and cognitive decline in AD patients [39, 72].
These findings suggest that this toxic effect needs to be
targeted earlier or it could not be the only pathology lead-
ing to cell death and atrophy in symptomatic patients. In
addition to the effects of amyloid pathology, the impact of
tau pathology on white matter needs to be considered.
Tau can affect the normal function of neurons through a
toxic gain of function or a loss of its normal function in
stabilizing microtubules. Although severe neocortical
tauopathy occurs in later stages of AD and mostly affects
grey matter, phosphorylated tau transforms into neurofibril-
lary tangles in neurons as well as glial tangles in astrocytes, and oligodendrocyte alterations in AD animal models and human
Source
Pak et al. 2003
ed PDGFR- α positive
n WM lesions
No change in Myelinating
OLs in deep white matter
Simpson et al. 2007
ange in immature OLs Increased mature non-
myelinating OLs
Desai et al. 2010
Gagyi et al. 2011
Behrendt et al. 2013
Behrendt et al. 2013
1 Presenelin-1, OL oligodendrocyte, MAP microtubule associated protein, PDGFR
white matter, 3xTg-AD triple transgenic AD mouse model. APPPS1 mouse
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grey matter is associated with white matter abnormalities
and demyelination in AD patients [56, 57]. The increased
levels of calpain2 in the AD white matter, an indicator of
axonal loss, was shown to be associated with increased cor-
tical phosphorylated tau and amyloid [57] and the phos-
phorylated tau showed to be a predictor for white matter
hyperintensities [56].
Iron: During myelination, oligodendrocytes require 2–3
fold higher energy levels than other cell types in the CNS to
produce such an extensive amount of membrane. Oligoden-
drocytes synthesize cholesterol, a process that is highly
metabolically demanding, making them vulnerable to hypo-
perfusion, excitotoxicity, heavy metals, and free radicals that
induce oxidative stress. Oligodendrocytes have the highest
iron content of all cell types, which increases with age and
even further in AD [5]. Oligodendrocytes at all stages of their
differentiation, compared with other glial cells contain
smaller amounts of antioxidant agents (e.g. glutathione per-
oxidase) and only half of the glutathione reductase activity
[43]. Thus, a high iron content and a low antioxidant content
make oligodendrocytes one of the most vulnerable cell
classes to oxidative stress in the CNS. If oxidative stress is
exacerbated by age, it may lead to increased cell damage
[81]. Bartzokis by comparing a map of cortical myelination
with maps of Aβ deposition hypothesized that age-associated
myelin breakdown leads to iron release from oligodendro-
cytes and that this iron release promotes Aβ oligomerization
in the parenchyma [7].
Hypoxia/Ischemia: Deep white matter areas lie at the ends
of the CNS arterial circulation, making them susceptible to
decreases in blood flow and oxygenation. Some anterior and
posterior white matter lies in watershed zones between the
anterior cerebral and middle cerebral arteries and middle
cerebral and posterior cerebral arteries respectively. Vascular
pathology in these regions is greater in patients with AD
than in individuals without dementia [23, 69]. Late-stage
oligodendrocyte progenitors are more sensitive to hypoxic
or ischemic damage than early-stage progenitors and more
mature oligodendrocytes [3]. A recent rodent study, using
single cell RNA sequencing, identified a population of oligo-
dendrocyte precursors as vascular and leptomeningeal cells.
These OPCs are located along vessels and they show simila-
rities with pericyte lineage cells [51]. In addition, to
emphasize the importance of relationship between vascular
system and oligodendrocyte lineage cells Tsai showed that
those OPCs require the physical infrastructure provided by
the vascular system to facilitate their migration during de-
velopment [80].
Excitotoxicity: In general, oligodendrocytes show a great
vulnerability to excessive ATP and/or activation of glu-
tamate receptors [55]. Oligodendrocytes express a wide
variety of receptors and membrane channels (e.g. ionotro-
pic glutamate and ATP receptors, ligand gated Ca2+channels and P2x7 receptors). Because of the lack of the
GluR2 subunit in oligodendrocyte AMPA receptors, there
is a higher permeability to Ca2+ ions compared with neu-
rons [54]. Another example is the sustained activation of
p2x7 receptors in oligodendrocytes due to excitotoxicity
or to high levels of ATP/ADP/AMP, which leads to exces-
sive Ca2+ in the cytosol and the activation of apoptosis
through caspase-3 activation. Extensive activation of these
receptors can result in oligodendrocyte damage and sub-
sequently myelin destruction. Back and colleagues showed
maturation-dependent vulnerability of oligodendrocytes
caused by intracellular glutathione depletion [2]. In
addition, as we mentioned, oligodendrocytes and myelin
damage due to excitotoxicity and calcium dysregulation
could be an early pathological feature of AD [45, 60].
DNA damage: Age related DNA damage in myelinating
oligodendrocytes may contribute to myelin loss [81, 82].
Postmortem analysis of white matter lesions obtained from
aging individuals shows the presence of oxidative damage
(8-OHdG immunoreactivity) in oligodendrocyte nuclear
DNA. These cells are also positive for senescence markers
such as SA-β-gal [1]. In older adults, excessive DNA dam-
age occurs in vulnerable oligodendrocytes and the DNA re-
pair mechanism becomes overwhelmed. Studies of changes
in genomic integrity and genomic instability of oligodendro-
cytes in the white matter of patients and animal models
could illuminate the role of oligodendrocyte in white matter
damage and pathology of AD [81, 82]. In addition, oligo-
dendrocyte lineage transcription factor 2 (Olig2) is located
on chromosome 21 which is 6.8 Mb telomeric of the amyl-
oid precursor protein (APP) gene. The possibility of these
two genes interacting in a context of the disease needs to be
studied [75].
Discussion
A variety of structural, histopathological and biochemical
pathologies take place in the white matter of AD
patients (summarized in Fig. 3). In this review, we have
tried to answer two questions:
What changes occur in white matter in the course of
AD and what is the relationship between these
changes and the pathological hallmarks of the disease?
Radiological, pathological, and molecular changes occur in
the white matter of AD patients. Radiological markers of
white matter damage occur as early as 22 years before the
estimated age of symptom onset in humans who carry AD
mutations [49]. These white matter changes are believed to
reflect demyelination and axon damage [63]. It is possible
that the oligodendrocytes or the precursors responsible for
remyelination of these areas are altered in number and in
DNA stability or are functionally less efficient in the pres-
ence of genetic changes, oxidative stress, increased iron
Fig. 3 This figure summarizes the pathological cascades, and their relation with each other, occurring during the development of Alzheimer’s disease
in white matter and cortex. While ischemia, excitotoxicity, oxidative stress, and iron overload in white matter damage oligodendrocytes, on one hand,
and amyloid toxicity affects them, on the other hand, the iron released from damaged oligodendrocytes promotes amyloid polymerization and
deposition in grey matter. The consequent demyelination and axonal loss result in further white matter damage and neuronal dysfunction. Neuronal
dysfunction is also a result of amyloid deposition in cortex and a proposed cause for white matter abnormalities in AD patients. White matter
hyperintensities are labelled with red in the MRI (FLAIR) scan of an AD patient. Blue arrows: direction of the damages originating in grey matter.
Maroon arrows: direction of the damages originating in white matter. LV lateral ventricle
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white matter damage in AD, there are chemical alterations
marked by loss of proteins and cholesterol. The decreases in
the levels of myelin proteins, such as myelin basic protein
(MBP), myelin proteolipid protein (PLP) and CNPase, in
white matter reflects the changes in oligodendrocytes and
myelin sheaths. In animal models of AD, the white matter
disruption and changes in myelin marker expression are
among the earliest pathological changes [16, 30]. Although
white matter changes are believed to be partly related to
neuronal degeneration in the cortex [57], there is also evi-
dence that oligodendrocyte and myelin pathology, which are
detected in AD mouse models, are affected prior to appear-
ance of amyloid and cortical pathology. It is not clear if these
changes are independent of cortical pathology or the cortical
structural damages are beyond the detection limits of
methods at early stages of the disease [29, 30, 40] and subtle
neurodegenerative changes could precede or promote white
matter changes even if they are not detectable with conven-
tional methods. In terms of therapeutic implications,
contemporary clinical trials have focused on the removal of
fibrillar forms of amyloid protein as a primary target, moti-
vated by the “amyloid hypothesis” that has dominated the
field’s conceptualization of the disease for many years [73].
Accordingly, interventions that target the removal ofamyloid would arrest the progression of disease and
improve cognitive outcomes. However, to date, clinical trials
aimed to clear Aβ plaques in AD have not resulted in clin-
ical improvement or reduction in the rates of disease pro-
gression. New strategies for disease treatment and
prevention are therefore necessary. The consistent observa-
tions that implicate white matter abnormalities in AD
pathogenesis and progression point to opportunities to tar-
get potential novel mechanisms implicated in the disease.
Are the clinical changes in AD secondary only to the
cortical hallmarks of the disease or do white matter
abnormalities contribute directly or indirectly to the
disease?
Beside amyloid hypothesis as the cause of AD, it is
crucial to note that there is a weak association between
amyloid plaques and AD symptoms [5]. Further, senile
plaques can be found in about 20–40% of older adults
without symptoms of dementia and cognitive impair-
ment [14, 62]. As discussed above, myelin loss contrib-
utes to cognitive decline in humans [67, 83] and in AD
animal models, early changes in white matter are
followed by the first cognitive impairment detected after
intracellular accumulation of Aβ but before Aβ plaques
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ation or axonal damage could directly and/or indirectly
affect cognition. Future studies with the aim of repairing
myelin loss could clarify the impact of white matter
changes on AD pathogenesis and may have therapeutic
benefit. In addition, dysfunctional oligodendrocytes early
in the course of the disease may not be able to play a
protective role for neurons and their axons. Hence, the
process of remyelination and myelin repair will be af-
fected. Signal conductivity, and synchronicity of im-
pulses, which are required for information processing
between neurons, depend on the amount of myelin pro-
duced by oligodendrocytes and therefore will be affected
[10]. In general, a number of animal AD model studies
suggest that white matter pathology emerges prior to ap-
pearance of cortical plaques and tangles [29, 30, 40]. Hu-
man studies with autosomal dominant forms of AD
suggest that Aβ levels begin to change as early as 25–
30 years prior to symptom onset, followed by tau path-
ology about 15 years prior to symptom onset, cerebral
hypometabolism, brain atrophy, and cognitive and func-
tional deficits [9, 29]. As noted above white matter abnor-
malities are also early findings in these patients [49], but
causal relationships among AD biomarkers in humans are
difficult to infer even from observed temporally-ordered
observations; white matter changes appear to emerge con-
temporaneously with other AD pathology, but it is unclear
if one is causing the other. Studies of 3xTg-AD triple trans-
genic AD mice show that the first pathological features
start to appear in 2 to 6-month old mice as white matter
disruption and changes in myelin marker expression in the
hippocampus and entorhinal cortex. At this age, the mice
do not show learning or memory deficits [16, 30]. Cognitive
impairment emerges after at around 3 to 6-months of age
[29]. The studies discussed regarding vascular insufficiency
in white matter suggest that the white matter pathology is
not caused by cortical pathology. On the other hand, neur-
onal accumulation of tangles and neuronal death will lead
to axonal loss in white matter [57]. It is not clear how this
would produce white matter hyperintensities in deep white
matter, however, it could well contribute to a more wide-
spread decrease in axons and myelin.
In conclusion, the various observations suggest that
white matter abnormalities and in particular impaired
myelin and oligodendrocytes could promote cognitive im-
pairment and AD pathology and could be the important
targets for studying and early treatments of AD. Future
studies with the aim of repairing myelin damage, beside
other efforts focused on the hallmark of Alzheimer’s dis-
ease, could elucidate the impact of white matter changes
as one of the core pathologies of AD.
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